Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients
Public ClinicalTrials.gov record NCT02826486. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
Study identification
- NCT ID
- NCT02826486
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- BioLineRx, Ltd.
- Industry
- Enrollment
- 80 participants
Conditions and interventions
Conditions
Interventions
- BL-8040 Drug
- Chemotherapy Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2016
- Primary completion
- Sep 5, 2022
- Completion
- Sep 5, 2022
- Last update posted
- Aug 27, 2024
2016 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| Honor Health | Scottsdale | Arizona | 85258 | — |
| Ochsner Medical Center | New Orleans | Louisiana | 70121 | — |
| Massachusetts General Hospital (MGH) | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center (BIDMAC) | Boston | Massachusetts | 02215 | — |
| DF/HCC | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Center, Wayne State University | Detroit | Michigan | 48201 | — |
| Washington University of St Louis | St Louis | Missouri | 63110 | — |
| Atlantic Medical Group | Morristown | New Jersey | 07962 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| Cornell Medical College | New York | New York | — | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02826486, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2024 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02826486 live on ClinicalTrials.gov.